URMC / Research / Clinical Trials / Study Details UMDS18092 / Mendler MDS Pilot IIT / Jason MendlerResearch Question:What is the safety and tolerability of combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS)?Basic Study Information Purpose:The primary objective of this study is to determine the safety and tolerability of combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS). A secondary objective is to determine the response to treatment (based on bone marrow and peripheral blood findings). A tertiary objective is to determine the impact of therapy on health-related quality of life (HRQOL) and patient-reported outcomes (PRO). A quaternary (scientific) objective is to determine the impact of treatment on both hematopoietic and stromal cell populations within the bone marrow of MDS patients. Location: University of Rochester Medical CenterStudy Reference #: UMDS18092Lead Researcher (Principal Investigator) Lead Researcher: Jason Mendler Study Contact InformationStudy Coordinator: Amber JohnsonEmail: amber_johnson@urmc.rochester.edu Additional Study Details Contact This Study First Name * This field is required Middle Name Last Name * This field is required Phone Number Email I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *You must agree to be contacted to continue. Please call me during the day. Please call me during the evening. Message Thank you for contacting us. People like you are helping URMC make our community and world a healthier place. We sincerely appreciate your effort. A member of our research team will be in touch with you. URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search